To include your compound in the COVID-19 Resource Center, submit it here.

Leveraging ViroPharma

Lev Pharmaceuticals Inc. might not seem like an obvious choice to be acquired by ViroPharma Inc., which has been focused on infectious diseases and transplant medicine. ViroPharma, however, says it's a clear fit with its strategy of building franchises within narrowly focused specialized hospital markets.

ViroPharma will acquire Lev for $442.9 million ($355.6 million in cash and $87.3 million in stock) and

Read the full 612 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers